NCT06039137

The Effect of Switching the H1-antagonist Clemastine to Cetirizine in Premedication Regimens During Paclitaxel Treatment

The Effect of Switching the H1-antagonist Clemastine to Cetirizine in Premedication Regimens During Paclitaxel Treatment: 'The H1-SWITCH Study'

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 395 (actual)
• Sponsor: Erasmus Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this study the effect of substituting clemastine IV to cetirizine PO on the occurence of hypersensitivity reactions during paclitaxel chemotherapy will be investigated.

Detailed description

This is a single arm before-after study with a historic control cohort to evaluate the effect of a policy change (i.e. substitution of clemastine IV for cetirizine PO) regarding the premedication scheme on the incidence of HSR during paclitaxel based chemotherapy.

Conditions

• Solid Tumor

Interventions

Type	Name	Description
DRUG	Cetirizine	Subjects were treated with a paclitaxel premedication regimen which contained oral cetirizine instead of intravenous clemastine
DRUG	Clemastine IV	Subjects were treated with paclitaxel premedication containing clemastine 2 mg IV

Timeline

• Start date: 2022-06-01
• Primary completion: 2023-04-27
• Completion: 2023-10-31
• First posted: 2023-09-15
• Last updated: 2024-09-25

Locations

1 site across 1 country: Netherlands